BenevolentAI wants to harness full potential of AI to accelerate next generation of scientific advantages
BenevolentAI, a London-headquartered company that is applying artificial intelligence to accelerate biopharma drug discovery, has appointed a new chief technology officer.
The company, which also has a research facility in Cambridge, UK, designs AI technology to “better understand disease mechanisms and discover novel drug targets”.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.